PTSD Symptom Reduction by Propranolol Given After Trauma Memory Activation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00645450 |
Recruitment Status :
Terminated
(Difficulty recruiting subjects and loss of study physician for new job)
First Posted : March 27, 2008
Results First Posted : July 2, 2019
Last Update Posted : July 2, 2019
|
Sponsor:
VA Office of Research and Development
Information provided by (Responsible Party):
VA Office of Research and Development
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment |
Condition |
Posttraumatic Stress Disorders |
Interventions |
Drug: Propranolol Drug: Placebo |
Enrollment | 9 |
Participant Flow
Recruitment Details | |
Pre-assignment Details |
Arm/Group Title | Propranolol | Placebo |
---|---|---|
![]() |
Weekly doses of short and long acting propranolol following recollection of traumatic memory | Weekly doses of placebo following recollection of traumatic memory |
Period Title: Overall Study | ||
Started | 5 | 4 |
Completed | 5 | 4 |
Not Completed | 0 | 0 |
Baseline Characteristics
Arm/Group Title | Propranolol | Placebo | Total | |
---|---|---|---|---|
![]() |
Weekly doses of short and long acting propranolol following recollection of traumatic memory | Weekly doses of placebo following recollection of traumatic memory | Total of all reporting groups | |
Overall Number of Baseline Participants | 5 | 4 | 9 | |
![]() |
Participants included combat Veterans of Afghanistan and Iraqi wars.
|
|||
Age, Categorical
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 5 participants | 4 participants | 9 participants | |
<=18 years |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Between 18 and 65 years |
5 100.0%
|
4 100.0%
|
9 100.0%
|
|
>=65 years |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||||
Number Analyzed | 5 participants | 4 participants | 9 participants | |
28 (4.62) | 25.5 (.71) | 27 (3.39) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 5 participants | 4 participants | 9 participants | |
Female |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Male |
5 100.0%
|
4 100.0%
|
9 100.0%
|
|
Region of Enrollment
Measure Type: Count of Participants Unit of measure: Participants |
||||
United States | Number Analyzed | 5 participants | 4 participants | 9 participants |
5 100.0%
|
4 100.0%
|
9 100.0%
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Dr. Scott P. Orr |
Organization: | Manchester VA Medical Center |
Phone: | 603-624-4366 ext 6565 |
EMail: | scott.orr@va.gov |
Responsible Party: | VA Office of Research and Development |
ClinicalTrials.gov Identifier: | NCT00645450 |
Other Study ID Numbers: |
MHBA-013-07S |
First Submitted: | March 19, 2008 |
First Posted: | March 27, 2008 |
Results First Submitted: | February 10, 2014 |
Results First Posted: | July 2, 2019 |
Last Update Posted: | July 2, 2019 |